Table 2 Characteristics of D2T* and non-D2T patients at the start of treatment with the first b/tsDMARD
| Â | D2T n. 45 | non-D2T n. 110 | p |
|---|---|---|---|
Age, mean (SD), yrs | 50.1 (10.9) | 54.5 (14.6) | 0.07 |
Female gender, n. (%) | 41 (91.1) | 81 (73.6) | 0.03 |
BMI, mean (SD) | 27.2 (8.3) | 25.7 (5.7) | 0.27 |
Overweight, n. (%) | 25 (55.6) | 43 (39.1) | 0.09 |
Current smoker, n. (%) | 11 (24.4) | 24 (21.8) | 0.89 |
Hypertension, n. (%) | 24 (53.3) | 49 (44.5) | 0.41 |
CCI, mean (SD) | 1.1 (1.3) | 0.9 (1.2) | 0.36 |
Depression, n. (%) | 9 (20) | 14 (12.7) | 0.36 |
Disease duration, median (IQR), months | 15.1 (8-29.6) | 21.5 (11-46.1) | 0.02 |
DAS28, mean (SD) | 5.2 (0.7) | 4.1 (1.1) | < 0.001 |
SJC28, mean (SD) | 5.6 (3.3) | 3.5 (3.4) | 0.001 |
TJC28, mean (SD) | 10 (6.6) | 5.4 (4.6) | < 0.001 |
VAS pain, mean (SD), mm | 66.9 (19.9) | 55.6 (24.5) | 0.02 |
CRP, mean (SD), mg/dl | 1.2 (1.3) | 1.2 (1.8) | 0.87 |
RF and/or ACPA positive, n. (%) | 22 (48.9) | 76 (69.1) | 0.03 |
SHS erosions ≥ 1, n. (%) | 20 (44.4) | 47 (42.7) | 0.99 |
MTX, n. (%) | 39 (86.7) | 88 (80) | 0.45 |
MTX dose, mean (SD) | 19.5 (4.8) | 18.4 (4.7) | 0.20 |
Prednisone, n. (%) | 42 (93.3) | 82 (74.5) | 0.02 |
Prednisone dose, mean (SD), mg/day | 6.5 (3) | 5.9 (2.2) | 0.17 |